

The association of lipids with amyloid fibrils

Received for publication, October 19, 2021, and in revised form, May 31, 2022 Published, Papers in Press, June 8, 2022,
<https://doi.org/10.1016/j.jbc.2022.102108>

John M. Sanderson*

From the Department of Chemistry, Durham University, Durham, United Kingdom

Edited by Phyllis Hanson

Amyloid formation continues to be a widely studied area because of its association with numerous diseases, such as Alzheimer's and Parkinson's diseases. Despite a large body of work on protein aggregation and fibril formation, there are still significant gaps in our understanding of the factors that differentiate toxic amyloid formation *in vivo* from alternative misfolding pathways. In addition to proteins, amyloid fibrils are often associated in their cellular context with several types of molecule, including carbohydrates, polyanions, and lipids. This review focuses in particular on evidence for the presence of lipids in amyloid fibrils and the routes by which those lipids may become incorporated. Chemical analyses of fibril composition, combined with studies to probe the lipid distribution around fibrils, provide evidence that in some cases, lipids have a strong association with fibrils. In addition, amyloid fibrils formed in the presence of lipids have distinct morphologies and material properties. It is argued that lipids are an integral part of many amyloid deposits *in vivo*, where their presence has the potential to influence the nucleation, morphology, and mechanical properties of fibrils. The role of lipids in these structures is therefore worthy of further study.

There is a vast body of literature describing the self-aggregation and assembly of proteins into oligomers and insoluble fibrils rich in β -structure. This aggregation is associated with numerous conditions, including, amongst others, Parkinson's disease, Alzheimer's disease (AD), and Huntington's disease, and type II diabetes. Studies cover a range of fibril behavior, including their growth *in vitro* from purified proteins, the composition and structural features of deposits found *in vivo*, and *ex vivo* study of the molecular characteristics of fibrils isolated from natural sources. However, whilst there has been a large focus on the protein elements of these aggregates, in living tissues, these proteins are usually deposited alongside other components, including lipids, carbohydrates (1), metal ions, and even whole organelles in some cases, such as dementia with Lewy bodies (LBs) (2). It is noteworthy that the earliest accounts of amyloid deposits in the 18th and 19th centuries described them as "lardaceous" and "waxy" (3–5), with the term "amyloid" being adopted much later. In the 1960s, the lipid content of amyloid deposits began to be scrutinized in more detail, often leading to conclusions that

lipids were present as a contaminant (6, 7). The focus subsequently shifted to address protein aggregation. In recent years however, in the face of a wealth of data on peptide and protein assembly into fibrils, it has become apparent that membranes have a key role in accelerating assembly *in vivo* and driving assembling intermediates into conformations that are on-pathway for fibril formation (8–14). But whilst assembly processes have been well characterized under controlled conditions *in vitro*, a number of significant challenges remain in understanding both the processes that occur *in vivo* that lead to otherwise normal functioning peptides and proteins becoming directed down aberrant folding pathways and the parts of this process where cellular damage occurs. A particularly complex challenge is understanding the link between fibrillogenesis and biological outcomes, as it is frequently difficult to relate the *in vitro* behavior to the *in vivo* toxicity. Fibrils formed in the presence of lipids, for example, can exhibit differing morphologies according to the method of preparation (11, 14–17). For many diseases that involve the formation of amyloid fibrils, the precise physiological circumstances that trigger toxic fibril formation are still poorly characterized, and a number of phenomena lack detailed information at the molecular level, such as how changes in lipid composition are able to influence nucleation kinetics and fibril morphology (18, 19).

There has recently been a shift back toward examining amyloid fibrils in their biological context, including an examination of the presence of other molecular components that may influence their properties or provide evidence that can improve our understanding of their biological function. It is unsurprising that fibrils should be associated with membranes *in vivo*, as this reflects the environment in which they form. Fibers are often associated closely with bound lipids when studied *in vivo* and also sometimes when prepared *in vitro* in the presence of membranes. There are two general types of lipid association with fibrils: loose (easily removed by washing or mechanical disruption) and tight (persisting even after washing). This review is concerned with the nature of lipid association with fibrils and not with the mechanisms underlying fibril nucleation, except where this nucleation is responsible for lipid inclusion in the fibril structure.

Overview of amyloid assembly

Several good reviews of fibrillogenesis are available in the literature (10, 16, 20–23). A generic overview of the

* For correspondence: John M. Sanderson, j.m.sanderson@durham.ac.uk.

processes leading to the formation of fibrils is given in Figure 1. Key to the process is the adoption of misfolded conformations of a protein monomer or a peptide monomer. Brief descriptions of several proteins and peptides that are known to form amyloid fibrils are given in Box 1. In some circumstances, an unfolded protein or a misfolded protein will form amorphous aggregates. Many nonamyloidogenic proteins form amorphous aggregates with lipids (24, 25), and although these structures are not of direct interest to this review, it remains a salient point that it is necessary to demonstrate that a protein–lipid aggregate has a fibrillar structure.

Some misfolded conformations are able to nucleate and seed aggregation into extended aggregates rich in β -structure. This nucleation may happen when the monomer is associated with a membrane or in free solution and occurs during the lag phase of fibrillogenesis. It is a fundamental point that there are multiple pathways for fibril formation, many of which lead to fibrils with differing structural and morphological properties (14, 18, 26, 27). The biologically relevant morphology may be different from one produced from a purified protein *in vitro* under a given set of conditions. In many cases, it has been demonstrated that fibril formation is promoted following membrane binding of a protein monomer or a




Figure 1. An overview of the pathways leading to fibril formation. A–C, adapted from Ref. (53) under a Creative Commons license (CC BY 4.0) and show images of plaques obtained postmortem from the brains of AD sufferers using an immunochemical stain against A β . Dotted arrows indicate a route hypothesized to lead to nucleation via lipidation of a membrane-associated state (35). AD, Alzheimer's disease.

Box 1. Examples of well-studied proteins and peptides**Amyloid A β**

A β peptides form by processing of the β -amyloid precursor protein by β - and γ -secretases (4, 146). The role of lipids in A β fibril formation has been characterized extensively (4, 27, 32, 47, 147), including the influence of membrane composition on fibril morphology (18, 27). A β (1–42) is associated with diffuse plaques in the early stages of AD. Deposition begins on the plasma membrane (PM) in close proximity to cell protrusions (processes) and leads to the formation of an amorphous substance. The PM eventually disappears, and the deposits become more fibrillar (55).

 α -Synuclein

α -Synuclein (α -Syn) is found alongside lipids, carbohydrates, and organelles in LBs (2, 87). The membrane interactions of α -Syn have been well reviewed (9, 148–151). The peptide is unstructured in solution, becoming helical upon binding of its N-terminal regions to membranes containing anionic lipids (152–155). Fibril nucleation is strongly promoted in membrane-bound conformations (156, 90), some of which have been hypothesized to arise by peptide lipidation (35). Other PTMs modulate membrane interactions and aggregation (157), and the interplay between lipid homeostasis, mitochondrial function, and fibril formation is complex (158).

Human islet amyloid polypeptide (amylin)

The deposition of human islet amyloid polypeptide (hIAPP) fibrils in islet cells is a feature of type II diabetes mellitus (8, 159, 160). As with many amyloid-forming peptides, hIAPP is unstructured in solution, adopting an amphipathic helix when membrane bound (161, 162). Potential binding sites include the mitochondrial envelope (8, 155). Membrane interactions occur at the N terminus of the peptide (159, 163). The presence of membranes accelerates fibril formation and influences fibril morphology (41, 45, 163).

Tau

Tau proteins modulate the polymerization dynamics of microtubules in axons (164). In AD, tau becomes hyperphosphorylated and forms intracellular neurofibrillary tangles (165). Binding to membranes containing negatively charged lipids leads to an increase in helicity (166). Some tau variants bind to dimyristoyl-*sn*-glycero-3-phosphoglycerol monolayers and form membrane-bound fibrils (13).

Scrapie prion protein

Scrapie prion protein (PrP^{Sc}) is the abnormal scrapie form of the cellular prion protein (PrP). PrP is anchored to the cell surface by a glycosylphosphatidylinositol anchor (167), and binding to negatively charged membranes influences its folding (11, 101). PrP^{Sc} is also tightly associated with the membrane (100, 168, 169) but is resistant to detachment by PI-specific phospholipase C (170, 171). In some cases, PrP accumulation around neurons is associated with membrane degradation (172).

Other proteins

Other proteins that form aggregates with membrane lipids that are amyloid in nature include apolipoprotein A-II, which forms extracellular fibrils (52); immunoglobulin light chain, amyloid fibrils of which colocalize with lipids and cholesterol *in vivo* (although not *in vitro* or *ex vivo*) (103); and endostatin (173).

protein oligomer (14, 28–32). This acceleration is generally attributed to a combination of factors, including the bound protein adopting a more favorable conformation for nucleation, the concentration of the protein into a small volume, and changing the process from one occurring in bulk solution to one that is effectively a 2-dimensional process (28). It is notable that many proteins that are unfolded in solution adopt elements of secondary structure on binding to the membrane, and this is likely to be a key feature in their nucleation (22).

Although folded proteins are not on-pathway for fibril formation, it is nevertheless possible that post-translational changes can lead to modifications that tip the balance in favor of misfolding. The addition of an alkyl chain from 4-hydroxy-2-nonenal, a byproduct of lipid autoxidation, has been found to favor amyloid formation in some cases (33) and prevent fibril formation in others (34), although in the latter case, the peptide was extensively modified. The direct addition of acyl groups (lipidation) has also been proposed to drive some peptides into membrane-anchored conformations competent for fibril formation (35). In a similar manner, when artificially labeled *in vivo* with a glycosylphosphatidylinositol anchor, the fragment 1 to 42 of the amyloid- β peptide (A β (1–42)) was found to deposit much more rapidly than the

untagged peptide (36). Post-translational modifications (PTMs) such as lipidation may also affect the interfacial interactions between protofilaments as well as packing interactions within the protofilament core.

Following nucleation, at the end of the lag phase, the addition of further monomers to the oligomers leads to the formation of protofibrils, often the first detectable aggregates. Growth at this stage occurs over a period of hours to days and leads to the eventual formation of fibrils. These fibrils may then be subject to further changes, such as fragmentation and secondary seeding, which influence both the assembly kinetics and the final fibril morphology (37, 38). It is now generally recognized that the lower to intermediate molecular weight species, rather than the mature fibrils, are the toxic species that inflict damage to cell membranes (29, 39–43). Indeed, larger fibrils formed by a number of proteins are nontoxic, and some perform functional roles within the cell (44).

The role of membranes in fibril formation

Several key features of amyloid nucleation in membranes are influenced by the presence of a membrane. For many peptides, key fibrillation characteristics, such as the duration of the lag phase, the rate of fibril growth and fibril morphology,

vary significantly with changes in membrane lipid composition and peptide to lipid ratio. In many cases, nucleation is significantly accelerated in the presence of negatively charged lipids (41, 45, 46). In general, liposome models are able to replicate some of the features of fibrils found *in vivo*, but often the outcomes of experiments with liposomes are dependent on experimental details, such as whether a peptide is added to preformed liposomes or incorporated into the membranes during formation (18, 27, 47, 48). The dependence of the outcome on both the method of preparation and the membrane composition makes comparisons between fibrils formed *in vitro* and those isolated from tissues more challenging.

Oxidized lipids may also play a role in triggering nucleation. In some cases, such as lipids in which an unsaturated *sn*-2 acyl chain has been oxidatively cleaved to form a carboxyl group, these effects on nucleation may be a consequence of the presence of additional negative potential on the membrane surface and changes to the intrinsic curvature of the lipid (49). In some model systems, the presence of oxidized lipids produces a significant change in peptide behavior, leading to the formation of peptide–lipid aggregates with a helical appearance by microscopy as a consequence of significant membrane remodeling during peptide aggregation (49). Amyloid formation may not also be a unique feature of the plasma membrane, as oxidative damage to low-density lipoprotein leads to the formation of A β fibrils *in vivo* (50), and exosomes are also involved in the transport of many amyloid-forming proteins around the cell (51). Amyloid formation by proteins associated with high-density lipoprotein and lipid droplets has also been described (52).

Evidence for the presence of lipids in amyloid fibrils

Multiple studies of amyloid deposits *in vivo*, after isolation from natural sources (*ex vivo*), or formed *in vitro* in the presence of a source of lipids have found evidence for the presence of lipids in fibrillar structures. In the case of AD, brain tissues have been examined by numerous methods, with the most common being confocal imaging combined with vibrational spectroscopy, imaging by mass spectrometry (MS) or related methods, and lipidomics by chromatography combined with MS.

Studies of A β *in vivo*

The early stages of A β aggregation are characterized by the formation on the cell surface of diffuse amorphous structures (plaques) containing protein and little or no lipid (53, 54). These plaques typically form in contact with the highly curved cell protrusions of astrocytes or neurons (55, 56), and the protein within appears as randomly dispersed accumulations (Fig. 1A) (53). Following the formation of diffuse plaques, subsequent steps lead to a loss of cellular material, visualized as a disintegration of the PM. The assumption is often made that the lipids lost are incorporated into fibrils (55, 57). In one case, the lipids released into the medium were analyzed and found to consist predominantly of cholesterol, phospholipids, and the ganglioside GM1 (monosialotetrahexosylganglioside), with A β colocalizing with GM1 after fractionation by density gradient ultracentrifugation (15). The loss of cellular material eventually leads to the

formation of compact plaques and eventually classic cored plaques (Fig. 1, B and C, respectively). The rest of the discussion in this section concerns classic cored plaques containing A β .

A detailed review of the lipid content of these plaques, as identified through lipidomics studies, has recently been presented (58). In mouse models, relative to normal tissue, there is an accumulation of fatty acids, cholesterol, sulfatides, and phosphatidylethanolamine lipids in plaques, and a depletion of phosphatidylcholine (PC) lipids. In human tissues, there is an accumulation of numerous lipid species in plaques, including ceramides, gangliosides, lysolipids, and phosphatidylinositol (PI) lipids, alongside a depletion of cerebroside and sulfatides. For some phospholipid classes, including PC and phosphatidylethanolamine, there is no consistent pattern of enhancement or depletion. These examples demonstrate that for many lipid classes, the data are nuanced, with species-specific changes in lipid levels.

Fibrillar plaques from patients with AD have been scrutinized using fibril-specific dyes combined with other imaging methods, such as vibrational imaging, to enable both peptide and lipid distributions to be characterized (53, 54, 59, 60). Imaging of the lipid CH and peptide amide vibrations by coherent anti-Stokes Raman scattering combined with thioflavin S fluorescence to detect fibrils revealed a colocalization of lipids and peptide, but the distribution was not uniform (Fig. 2A) (54). High lipid intensities were found in parts of the plaque coincident with high levels of thioflavin S staining. The lipid structures formed were very heterogeneous and included a range of lipid morphologies, including stacked lamellae and larger vesicular structures, covering a large range of sizes up to ~25 microns. By Raman methods, it was found that the most intense lipid signals colocalized with amide I bands typical of a peptide β -structure, providing strong evidence of peptide–lipid colocalization. Distinctive methylene CH₂ vibrations characteristic of alkyl chains were found in the absence of vibrations from ester carbonyls or phosphate groups, and without the usual bands seen for cholesterol, consistent with an




Figure 2. Imaging of AD plaques *in vivo* to reveal their lipid distributions. A, extracted from Ref. (54) under a Creative Commons license (CC BY 4.0) and shows a 3D rendering obtained by coherent anti-Stokes Raman scattering (CARS) showing lipids (in yellow) distributed across the plaque in needle-like structures on the left and a more diffuse distribution on the right. B–D, adapted from Ref. (60) under a Creative Commons license (CC BY-NC 3.0) and depict different images of the same plaque isolated from a human AD patient. B and C, obtained by FTIR imaging, with red and blue corresponding to regions of high and low intensity, respectively. B, shows the amide I band, corresponding to β -sheet. C, the CH₂ stretching vibration, arising primarily from lipids. D, shows a conventional image, with the plaque core stained using Congo red and the nuclei stained using hematoxylin blue. AD, Alzheimer's disease.

incorporation of ceramides into the plaque. A transfer of acyl groups to the peptide *via* the lipidation route (35) (Fig. 1) would produce a similar outcome.

Common features of classic cored plaques, revealed by many studies, are that lipids are found in all locations from the core to the periphery of the plaque (53, 54, 59, 60), and there is a lipid-rich annulus around the peptide-rich central core of the plaque (Fig. 2, B–D). There is evidence that some metals, notably Cu, are enriched in the lipid-rich annulus, whereas others, including Zn and Fe, are enriched in the core (59, 61). The enrichment of lipid in the annulus is relative to both the core of the plaque and the surrounding tissue. It is apparent therefore, that A β peptides and lipids colocalize *in vivo* in the center of the plaque, and surrounding this, there is a significant perturbation of the lipid profile relative to the rest of the cell.

Amyloid fibrils extracted from diseased patients or animal models

Fibrils from a number of sources have been examined after extraction from diseased tissue. In the early days of amyloid research, amyloid preparations were usually associated with significant quantities of lipid. Much of this lipid could easily be removed by chemical extraction, and the lipid was usually viewed as a contaminant to the protein (6, 7). However, in most preparations of A β fibrils by this method, some of the lipid proved impossible to remove, leading to residual “contamination” of the fibrils with 1 to 2% by mass of lipid. Indeed, X-ray diffraction studies of some amyloid proteins *ex vivo* also reveal evidence for the presence of lipid (62, 63).

Early studies of the lipid content of amyloid fibrils by TLC, even whilst concluding that lipids were most likely present as a contaminant, noted high contents of cholesterol and fatty acids (6). A mixture of fatty acids was found with a composition that matched the fatty acid profile of the host cell. Neither the high fatty acid content nor the finding that peptides and lipids colocalized in sucrose flotation experiments could be accounted for. Covalent modification to serine residues by a fatty acyl group transferred from the lipid offers one potential explanation for the fatty acid content (35). Such a modification has been observed for other membrane-active peptides (64, 65) and would account for the presence of fatty acids in the fibrils after treatment with ammonium hydroxide should similar modifications to the amyloid peptides be present. Generally, early 20th century studies on amyloid fibrils found lipid contents of 1 to 10% by mass (7). More recently, lipids extracted from a range of sources of amyloid fibril, including AA, ATTR, A β_2 M, AL λ , and AL κ amyloidoses (66), a group of conditions resulting from a build-up of amyloid in particular organs and tissues, and AD (paired helical filaments of tau (67)), have been analyzed by high-performance TLC and MS. These preparations typically contain 1 to 16% lipid by dry weight. The major lipids present are cholesterol, sphingomyelin (SM), and sulfatides, plus smaller quantities of cholesterol esters and fatty acids (66). In the case of paired helical filaments, galactocerebrosides and PC lipids are also found. It is notable from both these studies that many components of lipid rafts are associated with fibrils. In the case of paired helical filaments, it is in

addition interesting that the fibrils, which are intracellular, are associated with lipids from the outer PM leaflet. This may potentially be a consequence of tau interactions with exosomes, which contain many of the same lipids as rafts (51, 68). Structural studies by cryo-EM of tau filaments extracted from the brains of patients with corticobasal degeneration (69) and AD (70) show the presence of regions weak density around the core β -structure that may reflect the presence of a more dynamic or transiently occupied structure than the rest of the core. These are nonproteinaceous and have been hypothesized to correspond a polyanion in the case of corticobasal degeneration, although they are currently unidentified.

A β fibrils formed in model systems

A number of *in vitro* studies have found evidence for the incorporation of lipids into A β fibrils. The addition of A β (1–42) protofilaments, formed in the absence of lipids, to supported bilayers of PC/cholesterol/GM1 (68:30:2 by weight) led to significant lipid loss from one leaflet of the membrane in a detergent-like manner (71). Whether the extracted lipids colocalized with the peptide was not investigated by this study. Similar effects were not found for the A β (1–42) monomer. A separate study of A β (1–42) activity by fluorescence methods on a supported bilayer composed of dioleoyl-*sn*-glycero-3-phosphocholine/SM/cholesterol/GM1 did however note uptake of a general lipid dye into fibrils, as well uptake of the GM1 component. The latter was probed using a GM1-specific marker (72). Lipid uptake was found for addition of either the monomer or the preformed aggregates over the surface.

A β (1–40) induces significant perturbation to membranes composed of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine/1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoglycerol (POPG)/cholesterol at a P:L of 1:20, leading to changes in the distribution of lipids and ultimately membrane disruption, concomitant with the growth of fibrils (73). At the molecular level, many of the details of this fibrillation, such as fibril morphology and formation kinetics, are significantly affected by whether the monomeric peptide is preincorporated with the lipids prior to membrane formation or added afterward to preformed membranes. For preincorporated samples, short curved fibrils are observed after a period of 4 h, whereas for the peptides added after membrane formation, long and more ordered filament-like fibrils begin to be visible after 46 h. When liposomes containing lipids tagged with a fluorescent label are used, emission intensity changes are observed during fibril formation that are suggestive of an uptake of lipids into the fibrils.

Studies of A β (1–40) by solid-state NMR (ssNMR) in a related membrane model containing GM1 in addition to 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine/POPG/cholesterol have suggested that the peptide has a detergent-like activity, principally through the observation of isotropic ^{31}P signals at 0 ppm, consistent with fast-tumbling aggregates such as micelles (18). However, different results were obtained with total brain lipid extract, which serves to highlight that the outcome of many experiments *in vitro* is highly dependent on the experimental conditions. The presence of isotropic ^{31}P peaks in A β preparations studied by ssNMR has been noted on

other occasions however (73–75) and may be a common feature in many model systems reflecting a detergent-like activity of the peptide or the formation of lysolipids by lytic processes involving the peptide (35, 76).

Lipid inclusion into hIAPP fibrils

hIAPP has been well studied in model membranes. The addition of hIAPP to giant unilamellar vesicles (GUVs) labeled with a fluorescent lipid leads to a loss of the tagged lipid from the membrane (77, 78) and the formation of lipid aggregates that may contain peptide (8, 79). The peptide, as with other amyloid forming peptides, has been proposed to exert a detergent-like activity (80). This activity may be inhibited for the monomer in the presence of Ca^{2+} ions but is enhanced for fibrils in the presence of these ions (81).

Characterization of hIAPP fibers formed in a dipalmitoyl-*sn*-glycero-3-phosphoglycerol monolayer by tip-enhanced Raman spectroscopy revealed that the surface of the fibers was highly heterogeneous, although bands were detected that could be attributed to lipids that appeared to be partially coating the surface (82). Coating of hIAPP fibrils by lipids was also observed after administration of the peptide to a supported lipid bilayer (45). Following peptide addition, there was a rapid perturbation of bilayer integrity on a timescale of minutes, followed by the formation of proteinaceous fibrils. Vesiculation was observed at the point of contact between the fibril and the membrane, and fibrils became coated with lipid after a few hours.

A study of both GUVs and INS-1E cells by confocal microscopy using hIAPP tagged with a fluorescent label found significant colocalization of fibrils with lipids. In GUVs composed of dioleoyl-*sn*-glycero-3-phosphocholine/dipalmitoyl-*sn*-glycero-3-phosphocholine/cholesterol (1:2:1) containing an additional labeled lipid selective for the liquid disordered phase of the membrane, the peptide partitioned into the liquid disordered phase and formed fibrils that incorporated the labeled lipid. In INS-1E cells, using a different lipid label incorporated into the cell membrane prior to administration of the peptide, colocalization was also visualized (Fig. 3) (83).

Overall, there is strong evidence for the incorporation of lipid into fibrils formed by hIAPP.




Figure 3. Colocalization of hIAPP and plasma membrane lipids. BODIPY-labeled hIAPP (green channel) was administered to INS-1E cells in which the plasma membranes were labeled with a Texas red functionalized lipid (red channel). Images were acquired after 24 h. A, shows the green (peptide) channel, (B) the red (lipid) channel, and (C) the merged channels. The scale bar corresponds to 10 μm . Used from Ref. (83) with permission. hIAPP, human islet amyloid polypeptide.

α -Syn associates with lipids in vitro and in vivo

It has long been known that lipids, including SM, are found in LBs, thanks to classic work using lipid-selective stains (84). In fact, we now know that LBs are complex mixtures of materials from a range of subcellular sources (85, 86). Fibrils of α -Syn, when added to neurons and neurites, form LBs over a period of >14 days that incorporate lipids from a range of sources, including organelles (Golgi, endoplasmic reticulum, and mitochondria), the PM, lipid droplets, and lipoproteins. Lipid types include neutral lipids, cholesterol esters, and sphingolipids, amongst others (87). There has been a suggestion that there may not be a direct interaction between α -Syn fibrils and organelles (88), on the basis that fibrils formed by seeded growth in murine neurons, when observed by cryo-electron tomography, do not exhibit the expected abundance of observable membrane contacts. When fibril–membrane interactions were present, they did not produce any apparent membrane deformation. The presence of α -Syn fibrils in LBs, and the relationship between α -Syn fibril formation and LB formation, has also been questioned on the basis of cryo-EM studies of human postmortem brain tissue, in which LBs with immunoreactivity for α -Syn yielded low abundances of fibrils when examined by cryo-EM approaches (86). However, others have cautioned against overreliance on a single study by cryo-EM methods, partly because of the challenge of representing the whole sample when only a small portion may be analyzed, and partly because although filamentous structures are often observed, their compositions are often not characterized, and so it impossible to conclude whether they are composed of α -Syn (89).

A detailed study of the α -Syn nucleation process examined membrane preparations and soluble cytosolic fractions isolated from rat brain, alongside soluble preparations of human α -Syn obtained by recombinant methods (90). Although the rat peptide was distributed across both soluble and membrane fractions, no free peptide could be detected in the membrane preparations at any time point after isolation, regardless of the salt content of the buffer. This lack of observable dissociation is indicative of a very tight interaction between the peptide and the membrane. Membrane-bound rat α -Syn nucleated on incubation and was able to incorporate soluble human α -Syn added over the top. No aggregation was found in isolated cytosolic fractions, indicating that nucleation occurred in the membrane. In the oligomeric form, but not the soluble monomeric form, both human and rat α -Syn were detected in membrane fractions from sucrose flotation experiments. Coimmunoprecipitation experiments using antibodies specific for rat and human α -Syn produced a similar outcome. Overall, the pattern of behavior was consistent with nucleation occurring in the membrane, leading to the recruitment of oligomers from solution. Costaining of α -Syn aggregates in cells overexpressing α -Syn with an antibody specific for α -Syn and a lipid probe revealed significant colocalization of the two, indicative of significant incorporation of lipid into the α -Syn aggregates.

A key study showed a number of interesting phenomena consistent with lipid incorporation during early α -Syn fibril growth. In anionic membranes containing phosphatidylserines

or cardiolipins at pH 5.5, the peptide aggregated in domains after 2 h, with the domain size dependent on the aggregation state. After longer periods, as determined by imaging using a labeled peptide and a labeled lipid incorporated into the GUV membrane, structures growing from the surface of the GUVs were enriched in lipids (91).

Another key study on α -Syn fibrillation in anionic model membranes demonstrated lipid uptake into monomers formed following the addition of the monomer to membranes. Lipid uptake was confirmed by chromatography (TLC) and spectroscopy approaches (NMR). The outcome was dependent on P:L, with close association of lipids to nascent fibers at high P:L, and the absorption of vesicles to formed fibers at low P:L. Lipid uptake into the fibrils was a saturable process, suggesting the presence of specific interactions between the peptide and lipids, and resulted in morphological changes, such as a conversion from bundles of fibrils to tangles (92).

Other studies have found that α -Syn is able to extract lipids from anionic charged model membranes, including vesicles (93, 94) and supported lipid bilayers (95) leading to visible perturbations to membrane integrity, such as loss of material or the formation of aggregates containing both lipid and β -rich peptide. ssNMR has in addition provided evidence for the coassembly of α -Syn with membranes in vesicles composed of anionic lipids, with the aggregates exhibiting slower but more isotropic rotation of the lipids (96).

PrP aggregates associate with raft lipids

Monomeric PrP copurifies with fatty acids from hamster brain tissues (97). A number of lipid components have been identified in prion fibers isolated from the brains of rats and hamsters, including SM, galactosylceramides, PC, and cholesterol (98). These are generally assumed to be contaminants carried over during isolation, but nevertheless, the sphingolipids cannot be removed completely by solvent extraction. In a manner that echoes the studies described previously for α -Syn (90) and A β (6), a small quantity (about 2%) of PrP with high infectivity is found at low density, in this case, in the meniscus, after sucrose gradient ultracentrifugation of rat brain preparations (98). Despite this high flotation, the levels of lipids in this fraction were very small. Analysis of the lipid content of this fraction by MS revealed a similar profile to the lipids remaining in the fibers after solvent extraction. Nevertheless, the high flotation of the protein could not be accounted for by the low lipid levels. Isolation of PrP^{Sc} from native membranes in styrene maleic acid copolymers has enabled the lipids closely associating with protofilaments to be identified. The lipids identified include cholesterol, PI, and SM. PrP^{Sc} isolated from different animal models exhibits some species-specific profile differences, with, for example, triglycerides present in some but not others (99). Generally, lipids usually associated with lipid rafts are most commonly identified in association with prion aggregates (100).

In a study on model membranes, PrP interacting with GUVs labeled with fluorescent lipids exhibited the formation of extramembranous aggregates containing lipid, although the

protein content of these aggregates was not assayed for amyloid character in this particular study (101). Sho, a PrP with similarity to PrP, was observed to form fibrils in model anionic membranes. These fibrils were likely to contain lipids, as evidenced by the decrease in liposome size during their formation (102).

Other proteins forming lipid-associated aggregates

Additional examples exist where lipids have been found to copurify with fibrils. For example, fibrils of transthyretin from patients with familial amyloidotic polyneuropathy copurify with sphingolipids, phospholipids, acylglycerides, fatty acids, cholesterol, and cholesterol esters. As in other examples described previously, in this particular study, the lipids were treated as contaminants (63). Some proteins, such as the immunoglobulin light chain, show colocalization with lipids and cholesterol *in vivo* but not *ex vivo* or when fibrils are formed *in vitro* (103).

One study identified multiple proteins that formed amyloid in negatively charged membranes *in vitro*, including lysozyme, myoglobin, glyceraldehyde-3-phosphate dehydrogenase, insulin, transthyretin, cytochrome *c*, histone H1, and R-lactalbumin (46). These proteins share the feature of having clusters of cationic residues on their surface. Fiber formation was found to occur very rapidly after mixing (5–10 min), that is, on a timescale much faster than fibrils normally form in many systems *in vitro*. A separate study on cytochrome *c*, however, noted a considerable structural variation in the fibers, both between and within samples, with the protein adopting near-native conformations in some cases (24). Fibers with typical amyloid vibrational spectra were found at high P:L, but fibers with a higher lipid content yielded vibrational bands typical of helical structure and were more heterogeneous. This heterogeneity suggests that rapid modes of forming fibers may not be typical of the process that occur *in vivo* and are different from slower growth processes. It may be the case that the proteins contributing to these rapid forming fibers become trapped in a metastable state if the formation is too fast (24).

A number of studies have identified fibril-like assemblies of proteins with lipids in which the usual properties of amyloid fibrils are not observed. These proteins include some, such as lysozyme, that have previously described as amyloid forming (25, 104–106), alongside nonamyloidogenic proteins with other forms of membrane activity, such as bovine seminal plasma protein PDC-109 (107) and temporin B, an antimicrobial peptide (49). The seminal peptide PAP(248–286) forms coaggregates with POPG that have some amyloid-like properties, such as binding thioflavin T, but otherwise differ from amyloid forms of the peptide in forming rapidly (<5 min) and being poor at seeding the growth of further amyloid fibrils (108). In addition, these aggregates only form when there is a very high PG content. It has been suggested that the formation of protein–lipid aggregates, including amorphous aggregates, may be general feature of many proteins (49), but the ability of a protein to form aggregates with anionic lipids does not

guarantee that these aggregates will be amyloid in nature (105). In some cases, the use of dyes to detect amyloid formation in samples needs to be treated with caution. Thioflavin T, for example, exhibits enhanced fluorescence when bound in hydrophobic environments, such as cell membranes or micelles (109), and Congo red can exhibit nonspecific binding to the membranes of some cells (83).

As a final point, fibrils formed in membranes from apolipoprotein C-II using a labeled short-chain lysolipid (labeled in the headgroup) as a marker led to accelerated fibril formation but no uptake of the label into the fibrils (110). It may well be that there is no lipid uptake in this case. However, this lipid is unusual for this kind of study in being a lysolipid with a short acyl chain and will therefore not partition within the membrane in the same manner as other lipids. The acceleration could be due to transfer of the chain to the protein (35), which would in addition result in loss of the label.

When and how are lipids incorporated into fibrils?

The interactions between amyloid fibrils and lipids

It is insightful to examine amyloid structures determined using *ex vivo* material isolated from natural amyloid sources such as plaques and LBs, as many structures determined using samples prepared *in vitro* could not possibly include significant quantities of lipid unless prepared in the presence of an added source of lipid. This argument applies equally to fibrils grown *in vitro* that are seeded using an *ex vivo* amyloid. Fibril morphology is an outcome of competing nucleation processes, which themselves are influenced by numerous other factors, such as PTMs, membrane binding, and the presence of solutes such as anions (23, 27, 111–113). As a result, most fibril preparations are inhomogeneous, whether formed *in vitro* or isolated from a natural source. Structural variations are often apparent even within a single fibril. Furthermore, a single *ex vivo* seed is able to produce differing morphologies by changing the experimental conditions (114).

As a consequence, fibril structures produced *in vitro* may not reflect the influence of lipids on the morphology during nucleation. Natural amyloids represent structures where the presence of lipids has had the potential to influence morphology throughout fibril formation, even if lipid incorporation into the fibrils is stochastic and substoichiometric. It is a more reasonable assertion that, for a given amyloidogenic protein, a distribution of fibril morphologies characterizes the influence of lipids on fibril formation by that protein. Evidence to support this assertion arises from the observation that polymorphism of fibrils of α -Syn (113, 115, 116), hIAPP (117), A β seeded from AD brain amyloid (111, 112) and obtained *ex vivo* (118), plus other proteins (118, 119), is often found within material isolated from the same natural sample. In addition, the morphologies of A β filaments and aggregates are influenced by the presence of lipid membranes and their lipid composition (19, 26, 27). The range of morphologies formed by the same protein in the absence of lipids is likely to be different to, but may overlap with, those found in the presence of lipids.

In recent years, the structures of several amyloids have been determined *ex vivo*, typically by using cryo-EM on the material itself, or using the material to seed further fibril growth to obtain material for ssNMR studies. All these structures (Fig. 4) reveal the characteristic amyloid motifs, including parallel cross β -sheets and β -helices (120), and typically have a highly folded backbone, often comprising motifs such as S-shaped (16, 23, 114, 121) or Greek key folds (122, 123). Contacts between opposing β -sheets are stabilized by a combination of hydrophobic clustering, including steric zippers, and electrostatic interactions, including salt bridges and Asn-Gln ladders (23, 124–129). As a consequence, there is a striking segregation of hydrophilic and hydrophobic residues, particularly for structures obtained from fibers prepared *in vitro*. Many of the sites that are available for interaction with lipids are therefore either surface patches, such as those presented at the ends of fibrils, or gaps in the β -sheet structure into which the lipid can closely associate. Structures obtained directly on *ex vivo* material often contain cavities lined with hydrophilic residues. In some structures, these cavities contain polar solutes and anions (113), but in all cases, they are not sites that are able to accommodate the relatively large acyl chains of lipids. It should be remembered however, that lipids are less likely to be resolved in these structures if their inclusion in the fibril is stochastic and therefore not part of a regular matrix. There is also a potential for selection bias in favor of parts of the sample that are more homogeneous and ordered, and therefore likely to give resolvable density, but may contain less lipid.

The observation of fibrils in contact with lipid vesicles in several natural amyloid samples points to a close interaction between the fibril surface and membranes. Examples include A β fibrils, which colocalize in plaques with membranes in a diverse array of compositions and forms, ranging from lamellar stacks to vesicles (54), and α -Syn fibrils in LBs, where vesicles include organelles and other lysosome-like structures (87, 85, 86). Electron tomography imaging of material from a cell model for systemic amyloid A amyloidosis reveals a similar heterogeneous mixture of vesicles in contact with fibrils (119). Sites of close interaction between systemic amyloid A fibrils and vesicles are distinguishable by whether they involve contact with the ends of the fibrils, or sites along the fibril length, providing a clear indication that there is more than one mode of interaction between the fibrils and membranes. Interestingly, interaction with the fibril ends is the more common mode, involving around 6% of the fibrils in lipid-rich regions, and leads to deformation of the membrane at the contact site. This deformation is indicative of strong binding interactions at these sites, involving either fibril–lipid interactions, or interactions between fibrils and residual membrane proteins. Molecular level details of the interactions between membrane lipids and intact fibrils are scant. Interactions involving the fibril ends may derive from the initial binding of the amphiphilic peptide monomer with the membrane during nucleation, or be promoted by the presence of PTMs that anchor the peptide to the membrane, such as lipidation (35). Interactions along the fibril length are likely to be weaker if they only involve electrostatic interactions with the lipid




Figure 4. Illustrative examples of amyloid structures obtained directly from *ex vivo* material by cryo-EM or from amyloid fibrils prepared *in vitro* from an *ex vivo* seed. In all cases, only one structure from a series of polymorphic forms is presented. *A*, the structure of a tau filament studied by cryo-EM using material extracted from a patient with a globular glial tauopathy (PDB ID: 7P6C (174)). *B*, A β isolated from brain tissue of an Alzheimer's patient (PDB ID: 6SHS (175)). *C*, hIAPP seeded from amyloid extracted from the islet cells of a patient with type 2 diabetes (PDB ID: 6ZRF (117)). *D*, α -synuclein isolated from a patient with multiple system atrophy (PDB ID: 6XYO (115)). *E*, transthyretin isolated from a patient with ATTR amyloidosis (PDB ID: 6SDZ (176)). *F–J*, show space-filling representations of the corresponding structures in *A–E*. Hydrophobic and hydrophilic residues are colored blue and red, respectively (with His assigned as hydrophilic and Tyr as hydrophobic). Solid arrows indicate the location of polar cavities in the structures. Dashed arrows indicate the presence of hydrophobic cavities. hIAPP, human islet amyloid polypeptide; PDB, Protein Data Bank.

headgroups. Some fibrils have hydrophobic patches (23, 130, 131) that could contribute to stronger interactions with the membrane surface if the fibril surface is able to penetrate the membrane interface.

Sites of potentially much stronger lipid interaction with fibrils have been suggested by a number of ssNMR analyses of amyloid A β (1–40)–lipid complexes in aggregates formed when A β is preincorporated into liposomes during their preparation. These studies have revealed details of the molecular contacts between the peptide and the lipid (132–134). Close contacts are found in particular between the phosphorous atom of the lipid and the backbone carbonyl groups of residues Gly25 and Val36, with marginally weaker contacts to Gly29 and Gly33. No significant contacts are observed between the lipid headgroup and Gly9, Val12, Leu17, and Ala21. In general, the close interactions involve the loop segments of the core β -structure and the lipid headgroups, suggesting that lipids intercalate into the hydrophobic core of the sheets, disrupting the hydrogen bonding network (Fig. 5).

Similar to fibrils isolated from natural amyloid deposits, fibrils prepared *in vitro* from purified proteins or peptides are well known to exhibit a range of polymorphic forms that are adopted according to their conditions of preparation (17, 20, 26, 114). Fibrils formed from pairs of filaments typically have either rotational (C_2) or screw (2_1) symmetry with respect to the fibril axis. In some A β fibrils with rotational symmetry, such as those with threefold symmetry

(Fig. 5, *A* and *B* (135)), the outer sheet overhangs the inner sheet by two β -strands in the repeating unit along the fibril axis, providing a potential lipid interaction site. In line with the intercalation described previously, the head group of a lipid molecule is able to interact with Gly25 and the hydrophobic cluster in the center of the structure whilst occupying a position that has a good complementary fit with the inner strand structure. This interaction also facilitates other favorable noncovalent interactions, such as a cation– π interaction between the quaternary ammonium group of the lipid and the side chain of Tyr10. The rotational symmetry leads to equivalent interaction sites at each end of the repeating unit, leading to multiple potential interaction sites along the length of the fibril. Incorporation of lipids into filaments by intercalation in this manner would potentially yield structures with noninteger numbers of molecules per repeat, a scenario that has some precedent in filaments of A β and yeast PrPs, albeit for filaments formed in the absence of lipids (136).

This fibril morphology with a threefold rotational symmetry is also of interest because it appears to have a hydrophobic cavity large enough to accommodate one or more lipids whilst permitting close contact between the lipid headgroup and key residues (Fig. 5, *C* and *D*). It may be that fibril growth in the presence of lipids influences growth pathways in favor of morphologies with larger hydrophobic cavities to accommodate lipids. It is notable that this threefold symmetry has been




Figure 5. Representations of potential lipid-binding sites in fibrils of Aβ. In each case, a molecule of POPC has been manually docked onto a known peptide structure in an orientation and position consistent with proximity data from solid-state NMR measurements in order to illustrate relative size and fit. Hydrophobic and hydrophilic residues are colored *blue* and *red*, respectively (with His assigned as hydrophilic and Tyr as hydrophobic), apart from specific residues that are labeled in each structure. *A* and *B*, show an end view (*space filling*) and side view (*cartoon*) of an Aβ(1–40) structure with spherical symmetry (PDB ID: 2LMQ (135)) with a POPC molecule intercalated in the β-sheet structure. The side chain of Tyr10 is indicated with a *dagger*. *C* and *D*, show the same structure as *A/B*, but with a POPC molecule incorporated in the central cavity. Residues 1 to 8 of Aβ(1–40) are missing from this structure. However, residue 9 lies on the outside of the structure away from the central cavity. *E* and *F*, show opposing faces of an Aβ(1–42) fibril composed of two proto-filaments (PDB ID: 5OQV (142)) with helical symmetry, looking along the axis of the fibril. *G* and *H*, show POPC molecules docked onto the structure in *E*. *I*, shows a *cartoon* representation of the side view of the structure in *H*. Aβ(1–40), fragment 1 to 40 of the amyloid-β peptide; PDB, Protein Data Bank; POPC, 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine.

found for fibrils seeded from patients with AD (137). A hydrophobic cavity large enough to accommodate lipids in a predominantly β-sheet structure has a precedent in PM-endoplasmic reticulum lipid transport proteins (138–141). If lipid movement was permissible along the hydrophobic cavity of an amyloid filament, it would provide a means for lipid incorporation into growing filament ends that are distal from the membrane surface.

For fibrils with helical symmetry, the fibril ends are nonequivalent (142). Interestingly, this nonequivalence extends to the residues involved in the close contacts with lipids described previously (Fig. 5, *E* and *F*). On one face (Fig. 5*E*), the interacting residues are accessible, whereas on the other face (Fig. 5*F*), they are partially buried. Furthermore, these residues on the accessible face are positioned in a manner close to the hydrophobic cluster in the core of the fibril that would permit

simultaneous contact of the headgroup with the known contact sites determined by NMR and contact of the lipid acyl chains with the hydrophobic fibril core (Fig. 5, G–I). Should steric restrictions favor lipid interaction at one fiber end, lipid binding would have the potential to restrict fibril growth from that axis, thereby directing fibril growth from the other axis, with downstream effects on morphology and other structural features such as branching and fragmentation (Fig. 1). The differential incorporation of lipids into fibril ends to influence the growth axis may produce the variations in the fibril network observed in some samples, exemplified by serum amyloid A1 fibrils obtained in a cell model (119).

Lipid incorporation into fibrils

In the early stages of formation, interactions with membranes can promote nucleation, but there is limited opportunity for uptake of lipid material at this stage. The only available routes for uptake of parts of lipids are either by transfer of a fatty acyl group to a serine residue or a lysine residue of the peptide (35) or by transfer of a reactive aldehyde fragment derived from oxidative damage to a lipid (33). In some cases, the monomeric peptides or amyloid seeds may be able to exert a detergent-like activity, leading to loss of membrane material or remodeling of the membrane. Protein–lipid mixtures at this stage are a dispersion of protein in a predominantly lipid matrix. This stage of the process *in vivo* corresponds to the formation of diffuse plaques in AD (Fig. 1A).

Lipids are most likely to begin to associate with the nascent β -structures in the intermediate stages of fibril formation, during which oligomers and protofibrils begin to form (8, 78, 79, 91, 92). A recent study of A β fibril formation in flow conditions concluded that early forming fibrils and membranes form an equilibrium between the membrane-bound peptide and peptide–lipid aggregates in solution. This process implicitly favors the incorporation of lipids into fibrils at an early stage of fibril formation (143). This stage of the process is where the most toxic membrane-active species form and corresponds to the formation of compact structures in AD (Fig. 1B). Lipids incorporated into fibrils at this stage are likely to be tightly associated within the structure and correspond to those that remain following solvent extraction protocols on amyloid deposits isolated from diseased tissues. These lipids correspond to those incorporated into the structure by intercalation or inclusion in a hydrophobic cavity.

Larger fibrils, formed in the later stages of amyloid assembly, are generally less toxic than the early forming low-molecular weight assemblies. When preformed, these fibrils often exhibit low affinity for lipid membranes and yield little or no evidence of lipid uptake when added to membranes (66, 78). Those that do interact with membranes bind in a peripheral manner and either attach as inert structures (133, 134) or become coated in lipids adsorbed from the membrane (45, 72, 77, 92). These lipids are likely to be loosely associated and easily removed by chemical extraction of material isolated from amyloid deposits. This stage of fibril formation

corresponds to the classical core structure in AD (Fig. 1C), and the lipids are likely to be those in the lipid annulus around the protein core (Fig. 2).

It is finally worth remarking on the effects of lipids on the mechanical properties of fibrils. A systematic comparison of the effects of fibril formation in the presence and absence of lipids provides evidence that lipids can have a direct effect on the mechanical strength of fibrils. Fibrils formed by a fragment of serum amyloid A1 that were either isolated from their natural source or prepared *in vitro* from *ex vivo* seeds had a similar bending rigidity, as assessed by the persistence length of the fibrils. Amyloid fibrils formed by the same protein *in vitro* without seeding, or without the presence of lipids, formed fibrils with a higher bending rigidity (119). These observations suggest that lipid inclusion in the early stages of nucleation favors morphologies that are “softer” than protein-only fibrils formed *in vitro*, potentially as a consequence of having a higher helical content (144). A consequence of this lower mechanical strength for fibrils formed in the presence of lipids would be an increase in the rate of fibril fragmentation, with a concomitant increase in the rate of fibril growth (145).

Concluding remarks

It is apparent that, far from being the contaminants described in early preparations of amyloid fibrils, lipids are an integral part of most fibrillar deposits that form *in vivo* in association with disease states. Considering the evidence for the presence of lipids in amyloid fibrils across several amyloid-forming peptides, some common themes emerge. Many of these peptides associate with membranes as amphipathic helices and form fibrils in anionic membranes, usually with similar kinetics of nucleation and growth (hours to days). When studied *in vivo*, fibrils can be localized to structures rich in lipids and are isolated alongside lipids when extracted from diseased tissues, typically at a level of 1 to 15% lipid by dry mass. Chemical extraction of deposits from multiple sources fails to remove all traces of lipid, typically leaving behind 1 to 2% by mass. Many of these peptides, when separated by sucrose flotation, equilibrate to lower densities than expected. In model systems, these peptides can be demonstrated to form coaggregates with lipids. In favorable circumstances, there is clear evidence that the protein is in fibrillar form and that lipids are present. It seems likely that the presence of lipids in amyloid deposits is fundamental to the biology of these structures, particularly as membranes are known to influence the morphology and material properties of amyloid fibrils. The role of lipids in these structures is therefore worthy of further study.

Author contributions—J. M. S. is responsible for all aspects of this article.

Conflict of interest—The author declares no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: A β (1–42), fragment 1 to 42 of the amyloid- β peptide; AD, Alzheimer's disease; GM1, monosialotetrahexosylganglioside; GUV, giant unilamellar vesicle; hIAPP, human islet amyloid polypeptide; LB, Lewy body; MS, mass spectrometry; PC, phosphatidylcholine; PI, phosphatidylinositol; P:L, protein to lipid ratio; PM, plasma membrane; POPG, 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoglycerol; PrP, prion protein; PrP^{Sc}, scrapie prion protein; PTM, post-translational modification; SM, sphingomyelin; ssNMR, solid-state NMR; α -Syn, α -synuclein.

References

- Appel, T. R., Dumpitak, C., Matthiesen, U., and Riesner, D. (1999) Prion rods contain an inert polysaccharide scaffold. *Biol. Chem.* **380**, 1295–1306
- Lashuel, H. A., and Novello, S. (2021) Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein. *Neurobiol. Dis.* **156**, 105417
- Dickinson, W. H. (1867) On the nature of the waxy, lardaceous, or amyloid deposit. *Med. Chir. Trans.* **50**, 39–56.3
- Niu, Z., Zhang, Z., Zhao, W., and Yang, J. (2018) Interactions between amyloid β peptide and lipid membranes. *Biochim. Biophys. Acta* **1860**, 1663–1669
- Kyle, R. A. (2001) Amyloidosis: a convoluted story. *Br. J. Haematol.* **114**, 529–538
- Kim, I. C., Shirahama, T., and Cohen, A. S. (1967) The lipid content of amyloid fibrils purified by a variety of methods. *Am. J. Pathol.* **50**, 869–886
- Rimon, A. (1976) The chemical and immunochemical identity of amyloid. *Curr. Top. Microbiol. Immunol.* **74**, 1–20
- Saghir, A. E., Farrugia, G., and Vassallo, N. (2021) The human islet amyloid polypeptide in protein misfolding disorders: mechanisms of aggregation and interaction with biomembranes. *Chem. Phys. Lipids* **234**, 105010
- Xicoy, H., Wieringa, B., and Martens, G. J. M. (2019) The role of lipids in Parkinson's disease. *Cells* **8**, E27
- Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., et al. (2021) Amyloid oligomers: a joint experimental/computational perspective on Alzheimer's disease, Parkinson's disease, type II diabetes, and amyotrophic lateral sclerosis. *Chem. Rev.* **121**, 2545–2647
- Robinson, P. J., and Pinheiro, T. J. (2010) Phospholipid composition of membranes directs prions down alternative aggregation pathways. *Biophys. J.* **98**, 1520–1528
- Galvagnion, C., Buell, A. K., Meisl, G., Michaels, T. C., Vendruscolo, M., Knowles, T. P., et al. (2015) Lipid vesicles trigger α -synuclein aggregation by stimulating primary nucleation. *Nat. Chem. Biol.* **11**, 229–234
- Majewski, J., Jones, E. M., Vander Zanden, C. M., Biernat, J., Mandelkow, E., and Chi, E. Y. (2020) Lipid membrane templated misfolding and self-assembly of intrinsically disordered tau protein. *Sci. Rep.* **10**, 13324
- Gorbenko, G., Trusova, V., Gyrich, M., Adachi, E., Mizuguchi, C., and Saito, H. (2015) Interactions of lipid membranes with fibrillar protein aggregates. *Adv. Exp. Med. Biol.* **855**, 135–155
- Michikawa, M., Gong, J.-S., Fan, Q.-W., Sawamura, N., and Yanagisawa, K. (2001) A novel action of Alzheimer's amyloid β -protein (A β): oligomeric A β promotes lipid release. *J. Neurosci.* **21**, 7226–7235
- Willbold, D., Strodel, B., Schröder, G. F., Hoyer, W., and Heise, H. (2021) Amyloid-type protein aggregation and prion-like properties of amyloids. *Chem. Rev.* **121**, 8285–8307
- Riek, R. (2017) The three-dimensional structures of amyloids. *Cold Spring Harb. Perspect. Biol.* **9**, a023572
- Bera, S., Gayen, N., Mohid, S. A., Bhattacharyya, D., Krishnamoorthy, J., Sarkar, D., et al. (2020) Comparison of synthetic neuronal model membrane mimics in amyloid aggregation at atomic resolution. *ACS Chem. Neurosci.* **11**, 1965–1977
- Srivastava, A. K., Pittman, J. M., Zerweck, J., Venkata, B. S., Moore, P. C., Sachleben, J. R., et al. (2019) β -Amyloid aggregation and heterogeneous nucleation. *Protein Sci.* **28**, 1567–1581
- Almeida, Z. L., and Brito, R. M. M. (2020) Structure and aggregation mechanisms in amyloids. *Molecules* **25**, E1195
- Owen, M. C., Gnutt, D., Gao, M., Wärmländer, S. K. T. S., Jarvet, J., Gräslund, A., et al. (2019) Effects of *in vivo* conditions on amyloid aggregation. *Chem. Soc. Rev.* **48**, 3946–3996
- Scollo, F., and La Rosa, C. (2020) Amyloidogenic intrinsically disordered proteins: new insights into their self-assembly and their interaction with membranes. *Life* **10**, E144
- Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., et al. (2020) Half a century of amyloids: past, present and future. *Chem. Soc. Rev.* **49**, 5473–5509
- Alakoskela, J. M., Jutila, A., Simonsen, A. C., Pirneskoski, J., Pyhäjoki, S., Turunen, R., et al. (2006) Characteristics of fibers formed by cytochrome c and induced by anionic phospholipids. *Biochemistry* **45**, 13447–13453
- Coutinho, A., Loura, L. M., Fedorov, A., and Prieto, M. (2008) Pinched multilamellar structure of aggregates of lysozyme and phosphatidylserine-containing membranes revealed by FRET. *Biophys. J.* **95**, 4726–4736
- Cheng, Q., Hu, Z. W., Tobin-Miyaji, Y., Perkins, A. E., Deak, T., and Qiang, W. (2020) Fibrillization of 40-residue β -amyloid peptides in membrane-like environments leads to different fibril structures and reduced molecular polymorphisms. *Biomolecules* **10**, E881
- Rangachari, V., Dean, D. N., Rana, P., Vaidya, A., and Ghosh, P. (2018) Cause and consequence of A β – lipid interactions in Alzheimer disease pathogenesis. *Biochim. Biophys. Acta* **1860**, 1652–1662
- Hebda, J. A., and Miranker, A. D. (2009) The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: insights from type II diabetes. *Annu. Rev. Biophys.* **38**, 125–152
- Rawat, A., Langen, R., and Varkey, J. (2018) Membranes as modulators of amyloid protein misfolding and target of toxicity. *Biochim. Biophys. Acta* **1860**, 1863–1875
- Andreassen, M., Lorenzen, N., and Otzen, D. (2015) Interactions between misfolded protein oligomers and membranes: a central topic in neurodegenerative diseases. *Biochim. Biophys. Acta* **1848**, 1897–1907
- Byström, R., Aisenbrey, C., Borowik, T., Bokvist, M., Lindström, F., Sani, M. A., et al. (2008) Disordered proteins: biological membranes as two-dimensional aggregation matrices. *Cell Biochem. Biophys.* **52**, 175–189
- Munter, L. M. (2020) The lipid component of Alzheimer's disease research: an editorial highlight for “Brain region-specific amyloid plaque-associated myelin lipid loss, APOE deposition and disruption of the myelin sheath in familial Alzheimer's disease mice” on page 84. *J. Neurochem.* **154**, 7–10
- Babych, M., Nguyen, P. T., Côté-Cyr, M., Kihal, N., Quittot, N., Golizeh, M., et al. (2021) Site-specific alkylation of the islet amyloid polypeptide accelerates self-assembly and potentiates perturbation of lipid membranes. *Biochemistry* **60**, 2285–2299
- Qin, Z., Hu, D., Han, S., Reaney, S. H., Di Monte, D. A., and Fink, A. L. (2007) Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. *J. Biol. Chem.* **282**, 5862–5870
- Sanderson, J. M. (2020) Far from inert: membrane lipids possess intrinsic reactivity that has consequences for cell biology. *BioEssays* **42**, e1900147
- Nagarathinam, A., Höflinger, P., Bühler, A., Schäfer, C., McGovern, G., Jeffrey, M., et al. (2013) Membrane-anchored A β accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice. *J. Neurosci.* **33**, 19284–19294
- Habchi, J., Chia, S., Galvagnion, C., Michaels, T. C. T., Bellaiche, M. M. J., Ruggeri, F. S., et al. (2018) Cholesterol catalyses A β 42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. *Nat. Chem.* **10**, 673–683
- Dear, A. J., Meisl, G., Šarić, A., Michaels, T. C. T., Kjaergaard, M., Linse, S., et al. (2020) Identification of on- and off-pathway oligomers in amyloid fibril formation. *Chem. Sci.* **11**, 6236–6247
- Cline, E. N., Bicca, M. A., Viola, K. L., and Klein, W. L. (2018) The amyloid- β oligomer hypothesis: beginning of the third decade. *J. Alzheimer's Dis.* **64**, S567–S610

40. Janson, J., Ashley, R. H., Harrison, D., McIntyre, S., and Butler, P. C. (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. *Diabetes* **48**, 491–498
41. Engel, M. F. M., Khemtémourian, L., Kleijer, C. C., Meeldijk, H. J. D., Jacobs, J., Verkleij, A. J., *et al.* (2008) Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 6033–6038
42. Haataja, L., Gurlo, T., Huang, C. J., and Butler, P. C. (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. *Endocr. Rev.* **29**, 303–316
43. Konarkowska, B., Aitken, J. F., Kistler, J., Zhang, S., and Cooper, G. J. (2006) The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. *FEBS J.* **273**, 3614–3624
44. Jackson, M., and Hewitt, E. (2017) Why are functional amyloids non-toxic in humans. *Biomolecules* **7**, 71
45. Domanov, Y. A., and Kinnunen, P. K. (2008) Islet amyloid polypeptide forms rigid lipid-protein amyloid fibrils on supported phospholipid bilayers. *J. Mol. Biol.* **376**, 42–54
46. Zhao, H., Tuominen, E. K. J., and Kinnunen, P. K. J. (2004) formation of amyloid fibers triggered by phosphatidylserine-containing membranes. *Biochemistry* **43**, 10302–10307
47. Andrade, S., Loureiro, J. A., and Pereira, M. C. (2021) The role of amyloid β -Biomembrane interactions in the pathogenesis of Alzheimer's disease: insights from liposomes as membrane models. *ChemPhysChem* **22**, 1547–1565
48. Chang, Z., Deng, J., Zhao, W., and Yang, J. (2021) Exploring interactions between lipids and amyloid-forming proteins: a review on applying fluorescence and NMR techniques. *Chem. Phys. Lipids* **236**, 105062
49. Kinnunen, P. K., Domanov, Y. A., Mattila, J. P., and Varis, T. (2015) Formation of lipid/peptide tubules by IAPP and temporin B on supported lipid membranes. *Soft Matter* **11**, 9188–9200
50. Stewart, C. R., Tseng, A. A., Mok, Y. F., Staples, M. K., Schiesser, C. H., Lawrence, L. J., *et al.* (2005) Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. *Biochemistry* **44**, 9108–9116
51. Wang, G., Wang, Y., Liu, N., and Liu, M. (2020) The role of exosome lipids in central nervous system diseases. *Rev. Neurosci.* **31**, 743–756
52. Miyahara, H., Sawashita, J., Ishikawa, E., Yang, M., Ding, X., Liu, Y., *et al.* (2018) Comprehensive proteomic profiles of mouse AApoAII amyloid fibrils provide insights into the involvement of lipoproteins in the pathology of amyloidosis. *J. Proteomics* **172**, 111–121
53. Röhr, D., Boon, B. D. C., Schuler, M., Kremer, K., Hoozemans, J. J. M., Bouwman, F. H., *et al.* (2020) Label-free vibrational imaging of different A β plaque types in Alzheimer's disease reveals sequential events in plaque development. *Acta Neuropathol. Commun.* **8**, 222
54. Kiskis, J., Fink, H., Nyberg, L., Thyr, J., Li, J. Y., and Enejder, A. (2015) Plaque-associated lipids in Alzheimer's diseased brain tissue visualized by nonlinear microscopy. *Sci. Rep.* **5**, 13489
55. Yamaguchi, H., Maat-Schieman, M. L., van Duinen, S. G., Prins, F. A., Neeskens, P., Natté, R., *et al.* (2000) Amyloid beta protein (A β) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. *J. Neuropathol. Exp. Neurol.* **59**, 723–732
56. Kuragano, M., Yamashita, R., Chikai, Y., Kitamura, R., and Tokuraku, K. (2020) Three-dimensional real time imaging of amyloid β aggregation on living cells. *Sci. Rep.* **10**, 9742
57. Yanagisawa, K., Odaka, A., Suzuki, N., and Ihara, Y. (1995) GM1 ganglioside-bound amyloid beta-protein (A β): a possible form of preamyloid in Alzheimer's disease. *Nat. Med.* **1**, 1062–1066
58. Blank, M., and Hopf, C. (2020) Spatially resolved mass spectrometry analysis of amyloid plaque-associated lipids. *J. Neurochem.* **159**, 330–342
59. Summers, K. L., Fimognari, N., Hollings, A., Kiernan, M., Lam, V., Tidy, R. J., *et al.* (2017) A multimodal spectroscopic imaging method to characterize the metal and macromolecular content of proteinaceous aggregates ("Amyloid plaques"). *Biochemistry* **56**, 4107–4116
60. Liao, C. R., Rak, M., Lund, J., Unger, M., Platt, E., Albeni, B. C., *et al.* (2013) Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer's disease brain. *Analyst* **138**, 3991–3997
61. James, S. A., Churches, Q. I., de Jonge, M. D., Birchall, I. E., Streltsov, V., McColl, G., *et al.* (2017) Iron, Copper, and Zinc concentration in A β plaques in the APP/PS1 mouse model of Alzheimer's disease correlates with metal levels in the surrounding neuropil. *ACS Chem. Neurosci.* **8**, 629–637
62. Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., and Blake, C. C. (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. *J. Mol. Biol.* **273**, 729–739
63. Damas, A., Sebastião, M. P., Domingues, F. S., Costae, P. P., and Saraiva, M. J. (1995) Structural studies on FAP fibrils: removal of contaminants is essential for the interpretation of X-ray data. *Amyloid: J. Protein Folding Disorders* **2**, 173–178
64. Dods, R. H., Mosely, J. A., and Sanderson, J. M. (2012) The innate reactivity of a membrane associated peptide towards lipids: acyl transfer to melittin without enzyme catalysis. *Org. Biomol. Chem.* **10**, 5371–5378
65. Dods, R. H., Bechinger, B., Mosely, J. A., and Sanderson, J. M. (2013) Acyl transfer from membrane lipids to peptides is a generic process. *J. Mol. Biol.* **425**, 4379–4387
66. Gellermann, G. P., Appel, T. R., Tannert, A., Radestock, A., Hortschansky, P., Schroeckh, V., *et al.* (2005) Raft lipids as common components of human extracellular amyloid fibrils. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 6297–6302
67. Gellermann, G. P., Appel, T. R., Davies, P., and Diekmann, S. (2006) Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids. *Biol. Chem.* **387**, 1267–1274
68. Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., *et al.* (2006) Alzheimer's disease beta-amyloid peptides are released in association with exosomes. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 11172–11177
69. Zhang, W., Tarutani, A., Newell, K. L., Murzin, A. G., Matsubara, T., Falcon, B., *et al.* (2020) Novel tau filament fold in corticobasal degeneration. *Nature* **580**, 283–287
70. Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., *et al.* (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. *Nature* **547**, 185–190
71. Bode, D. C., Freeley, M., Nield, J., Palma, M., and Viles, J. H. (2019) Amyloid- β oligomers have a profound detergent-like effect on lipid membrane bilayers, imaged by atomic force and electron microscopy. *J. Biol. Chem.* **294**, 7566–7572
72. Sasahara, K., Morigaki, K., and Mori, Y. (2015) Uptake of raft components into amyloid β -peptide aggregates and membrane damage. *Anal. Biochem.* **481**, 18–26
73. Qiang, W., Yau, W. M., and Schulte, J. (2015) Fibrillation of β amyloid peptides in the presence of phospholipid bilayers and the consequent membrane disruption. *Biochim. Biophys. Acta* **1848**, 266–276
74. Qiang, W., Nam, M., and Akinlolu, R. D. (2015) Solid-state NMR studies of the membrane disruption induced by the β amyloid peptides: perspective and difficulties. *eMagRes* **4**, 315–322
75. Lau, T. L., Ambroggio, E. E., Tew, D. J., Cappai, R., Masters, C. L., Fidelio, G. D., *et al.* (2006) Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. *J. Mol. Biol.* **356**, 759–770
76. Britt, H. M., Prakash, A. S., Appleby, S., Mosely, J. A., and Sanderson, J. M. (2020) Lysis of membrane lipids promoted by small organic molecules: reactivity depends on structure but not lipophilicity. *Sci. Adv.* **6**, eaaz8598
77. Lee, C. C., Sun, Y., and Huang, H. W. (2012) How type II diabetes-related islet amyloid polypeptide damages lipid bilayers. *Biophys. J.* **102**, 1059–1068
78. Sparr, E., Engel, M. F. M., Sakharov, D. V., Sprong, M., Jacobs, J., de Kruijff, B., *et al.* (2004) Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. *FEBS Lett.* **577**, 117–120
79. Brender, J. R., Dürr, U. H. N., Heyl, D., Budarapu, M. B., and Ramamoorthy, A. (2007) Membrane fragmentation by an amyloidogenic

- fragment of human Islet Amyloid Polypeptide detected by solid-state NMR spectroscopy of membrane nanotubes. *Biochim. Biophys. Acta* **1768**, 2026–2029
80. Bag, N., Ali, A., Chauhan, V. S., Wohland, T., and Mishra, A. (2013) Membrane destabilization by monomeric hIAPP observed by imaging fluorescence correlation spectroscopy. *Chem. Commun.* **49**, 9155–9157
81. Sciacca, M. F., Milardi, D., Messina, G. M., Marletta, G., Brender, J. R., Ramamoorthy, A., *et al.* (2013) Cations as switches of amyloid-mediated membrane disruption mechanisms: calcium and IAPP. *Biophys. J.* **104**, 173–184
82. vandenAkker, C. C., Deckert-Gaudig, T., Schleege, M., Velikov, K. P., Deckert, V., Bonn, M., *et al.* (2015) Nanoscale heterogeneity of the molecular structure of individual hIAPP amyloid fibrils revealed with tip-enhanced Raman spectroscopy. *Small* **11**, 4131–4139
83. Radovan, D., Opitz, N., and Winter, R. (2009) Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol. *FEBS Lett.* **583**, 1439–1445
84. den Jager, W. A. (1969) Sphingomyelin in Lewy inclusion bodies in Parkinson's disease. *Arch. Neurol.* **21**, 615–619
85. Gai, W. P., Yuan, H. X., Li, X. Q., Power, J. T. H., Blumbergs, P. C., and Jensen, P. H. (2000) *In situ* and *in vitro* study of colocalization and segregation of α -synuclein, Ubiquitin, and lipids in Lewy bodies. *Exp. Neurol.* **166**, 324–333
86. Shahmoradian, S. H., Lewis, A. J., Genoud, C., Hench, J., Moors, T. E., Navarro, P. P., *et al.* (2019) Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. *Nat. Neurosci.* **22**, 1099–1109
87. Mahul-Mellier, A. L., Bartscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., *et al.* (2020) The process of Lewy body formation, rather than simply α -synuclein fibrillization, is one of the major drivers of neurodegeneration. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 4971–4982
88. Trinkaus, V. A., Riera-Tur, I., Martínez-Sánchez, A., Bäuerlein, F. J. B., Guo, Q., Arzberger, T., *et al.* (2021) *In situ* architecture of neuronal α -Synuclein inclusions. *Nat. Commun.* **12**, 2110
89. Lashuel, H. A. (2020) Do Lewy bodies contain alpha-synuclein fibrils? And does it matter? A brief history and critical analysis of recent reports. *Neurobiol. Dis.* **141**, 104876
90. Lee, H. J., Choi, C., and Lee, S. J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. *J. Biol. Chem.* **277**, 671–678
91. Grey, M., Linse, S., Nilsson, H., Brundin, P., and Sparr, E. (2011) Membrane interaction of α -synuclein in different aggregation states. *J. Parkinson's Dis.* **1**, 359–371
92. Hellstrand, E., Nowacka, A., Topgaard, D., Linse, S., and Sparr, E. (2013) Membrane lipid co-aggregation with α -synuclein fibrils. *PLoS One* **8**, e77235
93. Chaudhary, H., Subramaniam, V., and Claessens, M. M. A. E. (2017) Direct visualization of model membrane remodeling by α -synuclein fibrillization. *ChemPhysChem* **18**, 1620–1626
94. Chaudhary, H., Stefanovic, A. N., Subramaniam, V., and Claessens, M. M. (2014) Membrane interactions and fibrillization of α -synuclein play an essential role in membrane disruption. *FEBS Lett.* **588**, 4457–4463
95. Reynolds, N. P., Soragni, A., Rabe, M., Verdes, D., Liverani, E., Handschin, S., *et al.* (2011) Mechanism of membrane interaction and disruption by α -synuclein. *J. Am. Chem. Soc.* **133**, 19366–19375
96. Galvagnion, C., Topgaard, D., Makasevic, K., Buell, A. K., Linse, S., Sparr, E., *et al.* (2019) Lipid dynamics and phase transition within α -synuclein amyloid fibrils. *J. Phys. Chem. Lett.* **10**, 7872–7877
97. Deleault, N. R., Harris, B. T., Rees, J. R., and Supattapone, S. (2007) Formation of native prions from minimal components *in vitro*. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 9741–9746
98. Klein, T. R., Kirsch, D., Kaufmann, R., and Riesner, D. (1998) Prion rods contain small amounts of two host sphingolipids as revealed by thin-layer chromatography and mass spectrometry. *Biol. Chem.* **379**, 655–666
99. Esmaili, M., Tancowny, B. P., Wang, X., Moses, A., Cortez, L. M., Sim, V. L., *et al.* (2020) Native nanodiscs formed by styrene maleic acid copolymer derivatives help recover infectious prion multimers bound to brain-derived lipids. *J. Biol. Chem.* **295**, 8460–8469
100. Pinheiro, T. J. (2006) The role of rafts in the fibrillization and aggregation of prions. *Chem. Phys. Lipids* **141**, 66–71
101. Sun, Y., Hung, W. C., Lee, M. T., and Huang, H. W. (2015) Membrane-mediated amyloid formation of PrP 106–126: a kinetic study. *Biochim. Biophys. Acta* **1848**, 2422–2429
102. Li, Q., Chevalier, C., Henry, C., Richard, C. A., Moudjou, M., and Vidic, J. (2013) Shadoo binds lipid membranes and undergoes aggregation and fibrillization. *Biochem. Biophys. Res. Commun.* **438**, 519–525
103. Ami, D., Lavatelli, F., Rognoni, P., Palladini, G., Raimondi, S., Giorgetti, S., *et al.* (2016) *In situ* characterization of protein aggregates in human tissues affected by light chain amyloidosis: A FTIR microspectroscopy study. *Sci. Rep.* **6**, 29096
104. Coutinho, A., Loura, L. M., and Prieto, M. (2011) FRET studies of lipid-protein aggregates related to amyloid-like fibers. *J. Neurochem.* **116**, 696–701
105. Melo, A. M., Loura, L. M., Fernandes, F., Villalain, J., Prieto, M., and Coutinho, A. (2014) Electrostatically driven lipid-lysozyme mixed fibers display a multilamellar structure without amyloid features. *Soft Matter* **10**, 840–850
106. Melo, A. M., Ricardo, J. C., Fedorov, A., Prieto, M., and Coutinho, A. (2013) Fluorescence detection of lipid-induced oligomeric intermediates involved in lysozyme “amyloid-like” fiber formation driven by anionic membranes. *J. Phys. Chem. B* **117**, 2906–2917
107. Tannert, A., Kurz, A., Erlemann, K. R., Müller, K., Herrmann, A., Schiller, J., *et al.* (2007) The bovine seminal plasma protein PDC-109 extracts phosphorylcholine-containing lipids from the outer membrane leaflet. *Eur. Biophys. J.* **36**, 461–475
108. Vane, E. W., He, S., Maibaum, L., and Nath, A. (2020) Rapid formation of peptide/lipid coaggregates by the amyloidogenic seminal peptide PAP_{248–286}. *Biophys. J.* **119**, 924–938
109. Kumar, S., Singh, A. K., Krishnamoorthy, G., and Swaminathan, R. (2008) Thioflavin T displays enhanced fluorescence selectively inside anionic micelles and mammalian cells. *J. Fluoresc.* **18**, 1199–1205
110. Ryan, T. M., Griffin, M. D., Bailey, M. F., Schuck, P., and Howlett, G. J. (2011) NBD-labeled phospholipid accelerates apolipoprotein C-II amyloid fibril formation but is not incorporated into mature fibrils. *Biochemistry* **50**, 9579–9586
111. Paravastu, A. K., Qahwash, I., Leapman, R. D., Meredith, S. C., and Tycko, R. (2009) Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 7443–7448
112. Qiang, W., Yau, W. M., Lu, J. X., Collinge, J., and Tycko, R. (2017) Structural variation in amyloid- β fibrils from Alzheimer's disease clinical subtypes. *Nature* **541**, 217–221
113. Li, D., and Liu, C. (2021) Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease. *Nat. Chem. Biol.* **17**, 237–245
114. Ono, K., and Watanabe-Nakayama, T. (2021) Aggregation and structure of amyloid β -protein. *Neurochem. Int.* **151**, 105208
115. Schweighauser, M., Shi, Y., Tarutani, A., Kametani, F., Murzin, A. G., Ghetti, B., *et al.* (2020) Structures of α -synuclein filaments from multiple system atrophy. *Nature* **585**, 464–469
116. Mehra, S., Gadhe, L., Bera, R., Sawner, A. S., and Maji, S. K. (2021) Structural and functional insights into α -synuclein fibril polymorphism. *Biomolecules* **11**, 1419
117. Cao, Q., Boyer, D. R., Sawaya, M. R., Abskharon, R., Saelices, L., Nguyen, B. A., *et al.* (2021) Cryo-EM structures of hIAPP fibrils seeded by patient-extracted fibrils reveal new polymorphs and conserved fibril cores. *Nat. Struct. Mol. Biol.* **28**, 724–730
118. Annamalai, K., Gührs, K. H., Koehler, R., Schmidt, M., Michel, H., Loos, C., *et al.* (2016) Polymorphism of amyloid fibrils *in vivo*. *Angew. Chem. Int. Ed. Engl.* **55**, 4822–4825
119. Kollmer, M., Meinhardt, K., Haupt, C., Liberta, F., Wulff, M., Linder, J., *et al.* (2016) Electron tomography reveals the fibril structure and lipid interactions in amyloid deposits. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 5604–5609

120. Fitzpatrick, A. W., and Saibil, H. R. (2019) Cryo-EM of amyloid fibrils and cellular aggregates. *Curr. Opin. Struct. Biol.* **58**, 34–42
121. Hayward, S., and Kitao, A. (2021) The role of the half-turn in determining structures of Alzheimer's A β wild-type and mutants. *J. Struct. Biol.* **213**, 107792
122. Diaz-Espinoza, R. (2021) Recent high-resolution structures of amyloids involved in neurodegenerative diseases. *Front. Aging Neurosci.* **13**, 782617
123. Sun, Y., Hou, S., Zhao, K., Long, H., Liu, Z., Gao, J., et al. (2020) Cryo-EM structure of full-length α -synuclein amyloid fibril with Parkinson's disease familial A53T mutation. *Cell. Res.* **30**, 360–362
124. Wiegand, T., Malär, A. A., Cadalbert, R., Ernst, M., Böckmann, A., and Meier, B. H. (2020) Asparagine and glutamine side-chains and ladders in HET-s(218–289) amyloid fibrils studied by fast magic-angle spinning NMR. *Front. Mol. Biosci.* **7**, 582033
125. Zhang, M., Zhao, J., and Zheng, J. (2014) Molecular understanding of a potential functional link between antimicrobial and amyloid peptides. *Soft Matter* **10**, 7425–7451
126. Gallagher-Jones, M., Glynn, C., Boyer, D. R., Martynowycz, M. W., Hernandez, E., Miao, J., et al. (2018) Sub-ångström cryo-EM structure of a prion protofibril reveals a polar clasp. *Nat. Struct. Mol. Biol.* **25**, 131–134
127. Nelson, R., Sawaya, M. R., Balbirnie, M., Madsen, A.Ø., Riek, C., Grothe, R., et al. (2005) Structure of the cross-beta spine of amyloid-like fibrils. *Nature* **435**, 773–778
128. Lövestam, S., Schweighauser, M., Matsubara, T., Murayama, S., Tomita, T., Ando, T., et al. (2021) Seeded assembly *in vitro* does not replicate the structures of α -synuclein filaments from multiple system atrophy. *FEBS Open Bio* **11**, 999–1013
129. Wälti, M. A., Ravotti, F., Arai, H., Glabe, C. G., Wall, J. S., Böckmann, A., et al. (2016) Atomic-resolution structure of a disease-relevant A β (1–42) amyloid fibril. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E4976–E4984
130. Thacker, D., Sanagavarapu, K., Frohm, B., Meisl, G., Knowles, T. P. J., and Linse, S. (2020) The role of fibril structure and surface hydrophobicity in secondary nucleation of amyloid fibrils. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 25272–25283
131. Murphy, R. M. (2007) Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. *Biochim. Biophys. Acta* **1768**, 1923–1934
132. Qiang, W., Doherty, K. E., Klees, L. M., and Tobin-Miyaji, Y. (2020) Time-dependent lipid dynamics, organization and peptide-lipid interaction in phospholipid bilayers with incorporated β -amyloid oligomers. *J. Phys. Chem. Lett.* **11**, 8329–8336
133. Delgado, D. A., Doherty, K., Cheng, Q., Kim, H., Xu, D., Dong, H., et al. (2016) Distinct membrane disruption pathways are induced by 40-residue β -amyloid peptides. *J. Biol. Chem.* **291**, 12233–12244
134. Qiang, W., Akinlolu, R. D., Nam, M., and Shu, N. (2014) Structural evolution and membrane interaction of the 40-residue β amyloid peptides: differences in the initial proximity between peptides and the membrane bilayer studied by solid-state nuclear magnetic resonance spectroscopy. *Biochemistry* **53**, 7503–7514
135. Paravastu, A. K., Leapman, R. D., Yau, W. M., and Tycko, R. (2008) Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 18349–18354
136. Caspar, D. L. (2009) Inconvenient facts about pathological amyloid fibrils. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 20555–20556
137. Lu, J. X., Qiang, W., Yau, W. M., Schwieters, C. D., Meredith, S. C., and Tycko, R. (2013) Molecular structure of β -amyloid fibrils in Alzheimer's disease brain tissue. *Cell* **154**, 1257–1268
138. Li, P., Lees, J. A., Lusk, C. P., and Reinisch, K. M. (2020) Cryo-EM reconstruction of a VPS13 fragment reveals a long groove to channel lipids between membranes. *J. Cell Biol.* **219**, e202001161
139. Kumar, N., Leonzino, M., Hancock-Cerutti, W., Horenkamp, F. A., Li, P., Lees, J. A., et al. (2018) VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. *J. Cell Biol.* **217**, 3625–3639
140. Dziurdzik, S. K., and Conibear, E. (2021) The Vps13 family of lipid transporters and its role at membrane contact sites. *Int. J. Mol. Sci.* **22**, 2905
141. Osawa, T., Kotani, T., Kawaoka, T., Hirata, E., Suzuki, K., Nakatogawa, H., et al. (2019) Atg2 mediates direct lipid transfer between membranes for autophagosome formation. *Nat. Struct. Mol. Biol.* **26**, 281–288
142. Gremer, L., Schölzel, D., Schenk, C., Reinartz, E., Labahn, J., Ravelli, R. B. G., et al. (2017) Fibril structure of amyloid- β (1–42) by cryo-electron microscopy. *Science* **358**, 116–119
143. Iida, A., Abe, M., Nochi, M., Soga, C., Unoura, K., and Nabika, H. (2021) Promoted aggregation of A β on lipid bilayers in an open flowing system. *J. Phys. Chem. Lett.* **12**, 4453–4460
144. Schleegeer, M., vandenAkker, C. C., Deckert-Gaudig, T., Deckert, V., Velikov, K. P., Koenderink, G., et al. (2013) Amyloids: from molecular structure to mechanical properties. *Polymer* **54**, 2473–2488
145. Knowles, T. P., and Buehler, M. J. (2011) Nanomechanics of functional and pathological amyloid materials. *Nat. Nanotechnol.* **6**, 469–479
146. Chen, G. F., Xu, T. H., Yan, Y., Zhou, Y. R., Jiang, Y., Melcher, K., et al. (2017) Amyloid beta: structure, biology and structure-based therapeutic development. *Acta Pharmacol. Sin.* **38**, 1205–1235
147. García-Viñuales, S., Sciacca, M. F. M., Lanza, V., Santoro, A. M., Grasso, G., Tundo, G. R., et al. (2021) The interplay between lipid and A β amyloid homeostasis in Alzheimer's disease: risk factors and therapeutic opportunities. *Chem. Phys. Lipids* **236**, 105072
148. Runwal, G., and Edwards, R. H. (2021) The membrane interactions of synuclein: physiology and pathology. *Annu. Rev. Pathol.* **16**, 465–485
149. Suzuki, M., Sango, K., Wada, K., and Nagai, Y. (2018) Pathological role of lipid interaction with α -synuclein in Parkinson's disease. *Neurochem. Int.* **119**, 97–106
150. Alza, N. P., Iglesias González, P. A., Conde, M. A., Uranga, R. M., and Salvador, G. A. (2019) Lipids at the crossroad of α -synuclein function and dysfunction: biological and pathological implications. *Front. Cell. Neurosci.* **13**, 175
151. Heras-Garvin, A., and Stefanova, N. (2020) From synaptic protein to prion: the long and controversial journey of α -synuclein. *Front. Synaptic Neurosci.* **12**, 584536
152. Lee, E. N., Lee, S. Y., Lee, D., Kim, J., and Paik, S. R. (2003) Lipid interaction of alpha-synuclein during the metal-catalyzed oxidation in the presence of Cu²⁺ and H₂O₂. *J. Neurochem.* **84**, 1128–1142
153. Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2000) Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. *J. Biol. Chem.* **275**, 34393–34398
154. Fecchio, C., De Franceschi, G., Relini, A., Greggio, E., Dalla Serra, M., Bubacco, L., et al. (2013) α -Synuclein oligomers induced by docosa-hexaenoic acid affect membrane integrity. *PLoS One* **8**, e82732
155. Gilmozzi, V., Gentile, G., Castelo Rueda, M. P., Hicks, A. A., Pramstaller, P. P., Zanon, A., et al. (2020) Interaction of alpha-synuclein with lipids: mitochondrial cardiolipin as a critical player in the pathogenesis of Parkinson's disease. *Front. Neurosci.* **14**, 578993
156. Cholak, E., Bucciarelli, S., Bugge, K., Johansen, N. T., Vestergaard, B., Arleth, L., et al. (2019) Distinct α -synuclein:lipid Co-structure complexes affect amyloid nucleation through fibril mimetic behavior. *Biochemistry* **58**, 5052–5065
157. Bell, R., and Vendruscolo, M. (2021) Modulation of the interactions between α -synuclein and lipid membranes by post-translational modifications. *Front. Neurol.* **12**, 661117
158. Erskine, D., Koss, D., Korolchuk, V. I., Outeiro, T. F., Attems, J., and McKeith, I. (2021) Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. *Acta Neuropathol.* **141**, 511–526
159. Milardi, D., Gazit, E., Radford, S. E., Xu, Y., Gallardo, R. U., Caflich, A., et al. (2021) Proteostasis of islet amyloid polypeptide: a molecular perspective of risk factors and protective strategies for type II diabetes. *Chem. Rev.* **121**, 1845–1893
160. Roberts, A. N., Leighton, B., Todd, J. A., Cockburn, D., Schofield, P. N., Sutton, R., et al. (1989) Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. *Proc. Natl. Acad. Sci. U. S. A.* **86**, 9662–9666
161. Jayasinghe, S. A., and Langen, R. (2007) Membrane interaction of islet amyloid polypeptide. *Biochim. Biophys. Acta* **1768**, 2002–2009

162. Apostolidou, M., Jayasinghe, S. A., and Langen, R. (2008) Structure of alpha-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding. *J. Biol. Chem.* **283**, 17205–17210
163. Knight, J. D., and Miranker, A. D. (2004) Phospholipid catalysis of diabetic amyloid assembly. *J. Mol. Biol.* **341**, 1175–1187
164. Stamer, K., Vogel, R., Thies, E., Mandelkow, E., and Mandelkow, E. M. (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. *J. Cell Biol.* **156**, 1051–1063
165. Hall, G. F., and Patuto, B. A. (2012) Is tau ready for admission to the prion club. *Prion* **6**, 223–233
166. Künze, G., Barré, P., Scheidt, H. A., Thomas, L., Eliezer, D., and Huster, D. (2012) Binding of the three-repeat domain of tau to phospholipid membranes induces an aggregated-like state of the protein. *Biochim. Biophys. Acta* **1818**, 2302–2313
167. Stahl, N., Borchelt, D. R., Hsiao, K., and Prusiner, S. B. (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. *Cell* **51**, 229–240
168. Overduin, M., Wille, H., and Westaway, D. (2021) Multisite interactions of prions with membranes and native nanodiscs. *Chem. Phys. Lipids* **236**, 105063
169. Elfrink, K., Nagel-Steger, L., and Riesner, D. (2007) Interaction of the cellular prion protein with raft-like lipid membranes. *Biol. Chem.* **388**, 79–89
170. Wang, F., and Ma, J. (2013) Role of lipid in forming an infectious prion. *Acta Biochim. Biophys. Sin (Shanghai)* **45**, 485–493
171. Rouvinski, A., Karniely, S., Kounin, M., Moussa, S., Goldberg, M. D., Warburg, G., *et al.* (2014) Live imaging of prions reveals nascent PrP^{Sc} in cell-surface, raft-associated amyloid strings and webs. *J. Cell Biol.* **204**, 423–441
172. Jeffrey, M., Goodsir, C. M., Bruce, M. E., McBride, P. A., and Fraser, J. R. (1997) *In vivo* toxicity of prion protein in murine scrapie: ultrastructural and immunogold studies. *Neuropathol. Appl. Neurobiol.* **23**, 93–101
173. Zhao, H., Jutila, A., Nurminen, T., Wickström, S. A., Keski-Oja, J., and Kinnunen, P. K. (2005) Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. *Biochemistry* **44**, 2857–2863
174. Shi, Y., Zhang, W., Yang, Y., Murzin, A. G., Falcon, B., Kotecha, A., *et al.* (2021) Structure-based classification of tauopathies. *Nature* **598**, 359–363
175. Kollmer, M., Close, W., Funk, L., Rasmussen, J., Bsoul, A., Schierhorn, A., *et al.* (2019) Cryo-EM structure and polymorphism of A β amyloid fibrils purified from Alzheimer's brain tissue. *Nat. Commun.* **10**, 4760
176. Schmidt, M., Wiese, S., Adak, V., Engler, J., Agarwal, S., Fritz, G., *et al.* (2019) Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. *Nat. Commun.* **10**, 5008